5358 research outputs found
Sort by
Esercizio di impresa commerciale, conferimento di azienda e pex [Nota a sentenza Corte di cassazione, Sez. trib., 8 maggio 2019, n. 12138, Pres. Cirillo, Rel. D’Orazio]
No full textL'Italia: molti capitali, pochi capitalisti
No full textQuesto volume cerca di spiegare come l'Italia, partendo da condizioni di miseria al momento dell'unificazione del 1861, sia riuscita a risalire la china e a diventare una delle nazioni più ricche del mondo. La capacità di risparmio, frutto della paura di tornare poveri, ha giocato in questo "fenomeno" un ruolo rilevante. Partendo dall'epica di Ellis Island e delle angherie subite dagli emigrati italiani in terra straniera, il volume si addentra nelle viscere del capitalismo italiano, che ha visto sconfitte le grandi imprese private, spesso per incapacità manageriali, e al contempo ha scoperto, anche grazie a studiosi come Giorgio Fuà e Giacomo Becattini, la forza dei distretti industriali e delle medie imprese, il cosiddetto "quarto capitalismo", al cui interno le "multinazionali tascabili" sono andate senza timori reverenziali alla conquista dei mercati internazionali
Smartphone: strumento di comunicazione in sanità
No full textIl ceo di Apple ha dichiarato che "il più grande contributo che Apple può dare all'umanità riguarda la salute". Al di là dei risvolti chiaramente utilitaristici, è ormai chiaro che nuovi servizi sanitari offerti dalle app farebbero bene non solo alle aziende produttrici di smartphone, ma anche per incrementare la comunicazione interna tra professionisti e migliorare la comunicazione e il supporto offerto al paziente.The CEO of Apple has stated "the greatest contribution Apple can give to human kind concerns health". Beyond the purely utilitarian repercussions, nowadays it is clear that new health care services offered by app would favour not only smartphone manufacturers but they could also improve the internal communication among professionals and enhance the communication and the support offered to patients
HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer
No full textPurpose: To investigate the implications of the introduction of two hormonal therapies, abiraterone acetate + prednisone (AA+P) and enzalutamide (ENZA), for the treatment of naïve patients with metastatic castration-resistant prostate cancer (mCRPC) in the Italian setting. Methods: In 2017–2018, a Health Technology Assessment was conducted in Italy, considering the National Healthcare Service (NHS) perspective. Data were retrieved from literature evidence, economic evaluations, and qualitative questionnaires, considering the 9 EUnetHTA dimensions, and a final multi-criteria approach. Results: On the basis of mCRPC prevalence and incidence rates in Italy, the analysis considered 11,212 males eligible to either AA+P or ENZA treatments. Both drugs led to an improvement of the patients’ overall survival, with respect to the standard of care, composed of docetaxel chemotherapy. However, AA+P showed a higher rate of drug-related moderate adverse events and a monitoring activities incidence superior to ENZA (+70%, p-value=0.00), which led to a major resources absorption (€ 1,056.02 vs € 316.25, p-value=0.00), whereas ENZA showed a better cost-effectiveness average value (CEV: 54,586.12 vs 57,624.15). Economic savings ranging from 1.46% to 1.61% emerged for the NHS, as well as organizational advantages, with fewer minutes required for the mCRPC management (AA+P: 815 mins vs ENZA: 500 mins). According to experts’ perceptions, based on a 7-item Likert scale (ranging from −3 to +3), similar results emerged on ethical and social impact (ENZA: 1.35 vs AA+P: 1.48, p-value>0.05), and on legal dimension (ENZA: 0.67 vs AA+P: 0.67, p-value>0.05), since both drugs improved the patients’ quality of life and received approval for use. High-level perceptions related to ENZA adoption emerged with regard to equity (ENZA: 0.69 vs AA+P: 0.25, p-value<0.05), since it is cortisone-free. Multi-criteria approach analysis highlighted a higher score of ENZA than comparator (0.79 vs 0.60, p-value=0.00). Conclusion: The evidence-based information underlined the advantages of ENZA and AA+P treatments as therapeutic options for mCRPC patients. In the appraisal phase, the higher score than the comparator suggested ENZA as the preferred treatment for mCRPC
A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy
No full textAims: The aim of this study was to conduct a cost-effectiveness analysis, as well as a budget impact analysis, on the use of apremilast for the treatment of adult patients with psoriatic arthritis (PsA), within the Italian National Health Service (NHS). Methods: A Markov state transition cohort model, which was adapted to the Italian context, was used to compare the costs of the currently available treatments and of the patients’ quality of life with two alternative treatment sequences, with or without apremilast as pre-biologic therapy. Moreover, a budget impact model was developed based on the population of patients treated for PsA in Italy, who can be eligible for treatment with apremilast. The eligible population was represented by adult patients with PsA who had an inadequate response to or were intolerant to previous disease-modifying antirheumatic drugs (DMARDs), for the approved indication, and for the treatment studied in the economic analytic model. Results: This cost-effectiveness analysis estimated that the strategy of using apremilast before biologic therapy is cost-effective, with an incremental cost-effectiveness ratio of €32,263.00 per QALY gained which is slightly over the normal threshold found in other Italian economic studies, which usually considers a 40-year-period. Conversely, the budget impact analysis was conducted over 3 years, and it led to an estimated annual saving of €1.6 million, €4.6 million and €5.5 million in the first, second and third year of apremilast commercialization, respectively, for a total saving of €11.75 million in 3 years. Limitations: Limitations of this analysis include the absence of head-to-head trials comparing therapies included in the economic model, the lack of comparative long-term data on treatment efficacy, and the assumption of complete independence between the considered response rates to therapy. Conclusion: The use of apremilast as a first option before the use of biologic agents may represent a cost-effective treatment strategy for patients with PsA who fail to respond to, or are intolerant to, previous DMARD therapy. In addition, based on a budget impact perspective, the use of apremilast may lead to cost savings to the Italian healthcare system
Facebook: scontro tra poteri e giurisdizioni in Europa e Stati Uniti
No full textLa rassegna del diritto delle nuove tecnologie di questo mese tratta di un interessante “scontro” tra le giurisdizioni europea e statunitense, in particolare tra i poteri investigativi del Parlamento inglese relativamente alla disclosure delle email di rilevanti membri dello staff di Facebook sulla cessione di dati, da un lato e dall'altro lato il divieto di un giudice californiano della diffusione delle medesime email